替加色罗片对慢性便秘患者的消化不良症状、胃电活动、胃肠传输和肛管直肠功能的影响

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (11): 1311-1316.

替加色罗片对慢性便秘患者的消化不良症状、胃电活动、胃肠传输和肛管直肠功能的影响

李翠萍, 刘诗, 谢小平, 侯晓华

华中科技大学同济医学院附属协和医院消化内科, 武汉430022, 湖北

收稿日期:2007-08-03 修回日期:2007-10-19 发布日期:2020-11-04
通讯作者: 刘诗, 女, 博士, 教授, 博士生导师, 研究方向:胃肠疾病。Tel:027-85726447 E-mail: shiliugao@yahoo.com
作者简介:李翠萍, 女, 博士研究生, 研究方向:胃肠疾病。Tel:027-85726447 E-mail: cuipingli76@yahoo.com.cn

Effects of tegaserod on dyspeptic symptoms, electrogastrography, gastrointestinal transit and anorectal function in chronic constipation

LI Cui-ping, LIU Shi, XIE Xiao-ping, HOU Xiao-hua

Department of Gastroenterology, Union Hospital of Tongji Medical college, Huazhong University of Science and Technology, Wuhan 430022,Hubei,China

Received:2007-08-03 Revised:2007-10-19 Published:2020-11-04

摘要/Abstract

摘要： 目的: 研究口服替加色罗对慢性便秘患者伴随的消化不良症状、胃电活动、胃肠传输和肛管直肠功能的影响。方法: 43 例慢性便秘患者进行口服4周替加色罗6 mg 每日两次或安慰剂随机双盲治疗。治疗前后用消化不良症状问卷、不透X 线标记物法、胃电图和直肠肛管测压法评估患者消化不良症状、胃电活动、胃肠传输和肛管直肠功能的变化。结果: 与安慰剂组相比, 替加色罗组慢性便秘患者伴随的消化不良症状总积分治疗后较治疗前显著降低(11.57±3.24 vs 5.29±1.18, P =0.024) 。替加色罗组治疗后空腹-餐后胃电正常节律百分比变化较治疗前显著减小(6.58 %±1.29 % vs 11.80 %±3.85 %, P =0.044) 。替加色罗组患者胃内残余钡条数较治疗前显著减少(5.95±1.65 vs 4.57±1.65,P =0.036); 结肠内残余标记物数量(7.50±2.02 vs5.89±1.94, P =0.029) 较治疗前显著减少, 其中右半结肠(1.06±0.50 vs 0.67±0.23, P =0.035) 和直肠乙状结肠(3.33±1.28 vs 1.50±1.01, P =0.017)残余标记物数显著减少。替加色罗治疗后直肠排便窘迫阈值[(25.2±1.8) mm Hg vs (22.9±2.0) mmHg, P =0.028, 1 mm Hg =0.133 kPa] 和最大容量感觉阈值[(32.1±2.5) mm Hg vs (29.3±2.3) mmHg, P =0.043] 显著降低。替加色罗治疗后初次排便感觉阈值和肛管直肠压力较治疗前无统计学差异(P>0.05) 。结论: 替加色罗能改善慢性便秘患者的消化不良症状, 改善餐后胃电活动, 加速胃肠传输, 降低直肠感觉阈值, 提高直肠敏感性。

关键词: 替加色罗, 慢性功能性便秘, 消化不良症状, 胃电活动, 胃肠传输, 直肠肛管测压

Abstract: AIM: To assessment the effects of tegaserod 6 mg Bid on dyspeptic symptoms, electrogastrography, gastrointestinal transit and anorectal function in chronic constipation (CC). METHODS: The study consisted of a 2-week baseline period, a 4-week randomized, double-blind treatment period with tegaserod 6 mg Bid or placebo. The treatment was conducted in 43 patients with CC and symptoms of dyspepsia. Dyspeptic symptoms, gastric myoelectrical activity, gastrointestinal transit and anorectal function were evaluated before and after treatment of tegaserod or placebo. RESULTS: In comparison with placebo, ①total dyspeptic symptom scores in patients of CC treated with tegaserod 6mg Bid for 4 weeks were lower than before(11.57±3.24 vs 5.29±1.18, P =0.024); ②Tegaserod decreased normal percentages of postprandial electrogastroactivity (6.58 %±1.29 % vs 11.80 %±3.85 %, P =0.044); ③Tegaserod 6 mg Bid significantly accelerated markers in stomach(5.95±1.65 vs 4.57±1.65, P =0.036) and decreased those in the colon(7.50±2.02 vs 5.89±1.94, P =0.029); ④Tegaserod 6 mg Bid significantly decreased the sensation of defecation volume [(25.2±1.8) mm Hg vs (22.9±2.0) mm Hg, P =0.028] and maximal tolerable volume [(32.1±2.5) mm Hg vs (29.3±2.3) mm Hg, P = 0.043]; ⑤ There was no significant difference in the first sensation volume, rectal resting pressure, anal resting pressure andmaximal squeezing pressure after tegaserod treatment(P>0.05). CONCLUSION: Tegaserod 6 mg Bid for 4 weeks may relieve dyspeptic symptoms, significantly accelerate gastrointestinal transit and improve postprandial electrogastroactivity, and decrease the sensation of defecation volume and maximal tolerable volume in patients with with CC.

Key words: tegaserod, chronic constipation, dyspeptic symptoms, electrogastrography, gastrointestinal transit, rectoanal manometry

中图分类号:

R969

李翠萍, 刘诗, 谢小平, 侯晓华. 替加色罗片对慢性便秘患者的消化不良症状、胃电活动、胃肠传输和肛管直肠功能的影响[J]. 中国临床药理学与治疗学, 2007, 12(11): 1311-1316.

LI Cui-ping, LIU Shi, XIE Xiao-ping, HOU Xiao-hua. Effects of tegaserod on dyspeptic symptoms, electrogastrography, gastrointestinal transit and anorectal function in chronic constipation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(11): 1311-1316.

参考文献

1 郭晓峰, 柯美云, 潘国宗, 等.北京地区成人慢性便秘整群、分层、随机流行病学调查及其相关因素分析[J]. 中华消化杂志, 2002; 22:637-638.
2 Cheng C, Chan AO, HuiWM, et al.Coping strategies, illness perception, anxiety and depression of patients with idiopathic constipation:a population-based study[J]. Aliment Pharmacol Ther, 2003; 18:319-326.
3 Lin SR, Ke MY, Luo JY, et al.A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation[J]. World J Gastroenterol, 2007;13: 732-739.
4 Kamm MA, Mǜller-Lissner S, Talley NJ, et al.Tegaserod for the treatment of chronic constipation: A randomized, doubleblind, placebo-controlled multinational study[J]. Am J Gastroenterol, 2005; 100:362-372.
5 Degen L, Petrig C, Studer D, et al.Effect of tegaserod on gut transit in male and female subjects[J]. Neurogastroenterol Motil, 2005;17: 821-826.
6 Locke GR3rd, Zinsmeister AR, Fett SL, et al.Overlap of gastrointestinal symptom complexes in a US community[J]. Neurogastroenterol Motil, 2005; 17:29-34.
7 McColl KE, Murray LS, Gillen D, et al.Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsia[J]. BMJ, 2002;324: 999-1002.
8 Holtmann G, Talley NJ, Liebregts T, et al.A placebo-controlled trial of itopride in functional dyspepsia[J]. N Engl J Med, 2006;354:832-840.
9 Zhang J, Ouyang H, Zhu HB, et al.Development of gastric slow waves and effects of feeding in pre-term and full-term infants[J]. Neurogastroenterol Motil, 2006;18: 284-291.
10 Lu CL, Chen CY, Luo JC, et al.Impaired gastric myoelectricity in patients with chronic pancreatitis: role of maldigestion[J]. World J Gastroenterol, 2005;11:372-376.
11 Sarnelli G, Grasso R, Ierardi E, et al.Symptoms and pathophysiological correlations in patients with constipation and functional dyspepsia[J]. Digestion, 2005;71:225-230.
12 Yin J, Levanon D, Chen JD. Inhibitory effects of stress on postprandial gastric myoelectrical activity and vagal tone in healthy subjects[J]. Neurogastroenterol Motil, 2004;16:737-744.
13 van der Voort IR, Osmanoglou E, Seybold M, et al. Electrogastrography as a diagnostic tool for delayed gastric emptying in
14 functional dy spepsia and irritable bowel syndrome[J]. Neurogastroenterol Motil, 2003;15: 467-473.
15 Crowell MD, Mathis C, Schettler VA, et al.The effects of tegaserod, a 5-HT receptor agonist, on gastric emptying in a murine model of diabetes mellitus[J]. Neurogastroenterol Motil, 2005;17:738-743.
16 Cowan A, Earnest DL, Ligozio G, et al.Omeprazole-induced slowing of gastrointestinal transit in mice can be countered with tegaserod[J]. Eur J Pharmacol, 2005;517: 127-131.
17 Gremlich HU, Martinez V, Kneuer R, et al.Noninvasive assessment of gastric emptying by near-infrared fluorescence reflectance imaging in mice: pharmacological validation with tegaserod, cisapride, and clonidine[J]. Mol Imaging, 2004;3:303-311.
18 Tack J, Vos R, Janssens J, et al.Influence of tegaserod on proximal gastric tone and on the perception of gastric distension[J]. Aliment Pharmacol Ther, 2003;18: 1031-1037.
19 詹丽杏, 邹多武, 许国铭, 等.功能性便秘和便秘型肠易激综合征的结肠运输试验及直肠感觉阈值比较[J]. 中华消化杂志, 2002; 22:19-21.
20 Zar S, Benson MJ, Kumar D. Rectal afferent hypersensitivity and compliance in irritable bowel syndrome: differences between diarrhoea-predominant and constipation-predominant subgroups[J]. Eur J Gastroenterol Hepatol, 2006; 18:151-158.
21 Karlbom U, Lundin E, Graf W, et al.Anorectal physiology in relation to clinical subgroup s of patients with severe constipation[J]. Colorectal Dis, 2004; 6:343-349.
22 Fukushi E, Saito M, Sato H, et al. Functional roles of 5-hydroxytryptamine 3/4 receptors in neurons of rat dorsal motor nucleus of the vagus[J]. Neuroscience, 2006; 25;141:675-685.
23 焦红梅, 谢鹏雁.替加色罗对内脏高敏性大鼠直肠扩张后脊髓c-Fos 表达的影响[J]. 中华消化杂志, 2004;24: 480-483.
24 Coffin B, Farmachidi JP, Rueegg P, et al.Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects[J]. Aliment Pharmacol Ther, 2003; 17:577-585

[1]	欧阳冬生, 吴卫华, 谭志荣, 陈尧, 周淦, 胡东莉. 液相色谱–质谱法研究马来酸替加包罗片在中国健康受试者中的药代动力学特征[J]. 中国临床药理学与治疗学, 2007, 12(12): 1419-1423.
[2]	蒋萌, 熊宁宁, 周晓虹, 沈洪. 中药新药治疗慢性功能性便秘的临床试验设计特点[J]. 中国临床药理学与治疗学, 2005, 10(5): 594-597.